WB: Use at a dilution of 1/200. Detects a band of approximately 110 kDa. Optimal dilutions/concentrations should be determined by the end user.
Rat cortical membranes
The antibody does not cross reacts with PDE4D1, D2, D3, D4 and D5 variants. It also does not cross react with PDE4A, PDE4B or PDE4C.
Preservative: 0.02% Sodium Azide; Constituents: BSA
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.2 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide from unique region near N terminal of the PDE4D7 variant. (Rat)
Immunogen affinity purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Cyclic AMP dependent phosphodiesterase type D (PDE4D) family is comprised of 5 variants (PDE4D1, D2, D3, D4, D6, D7, and D8; 1, 2). One or more PDE4D subtype variants are ubiquitously present in all mammalian cells. In CNS all five PDE4D subtype variants are expressed in varying ratios, and their activity is regulated in tandem with GPCRs stimulation and selective phosphorylation by PKA and other kinases. Peripheral tissues also exhibit differential expression of PDE4D variants. PDE4D1/D2 mRNA levels rise in response to an increase in cAMP. Short term regulation of PDE4D variants involved PKA, MAP kinases and Erk2 phosphorylation that results in rapid change in their enzymatic activities. Other regulatory mechanism involved protein protein interactions with cytoskeletal scaffolding proteins. Anti PDE4D antibodies are ideal tools for studying regulation, expression, phosphorylation, and protein protein interactions of PDE4D variants employing pull down immunoprecipitation protocol.